Roivant Sciences
ROIV
52 hedge funds and large institutions have $1.72B invested in Roivant Sciences in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
24% more funds holding
Funds holding: 42 → 52 (+10)
0.92% more ownership
Funds ownership: 49.54% → 50.45% (+0.92%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
49% less call options, than puts
Call options by funds: $109K | Put options by funds: $212K
50% less capital invested
Capital invested by funds: $3.42B → $1.72B (-$1.69B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACG
Anchorage Capital Group
New York
|
+$31.9M |
| 2 |
AIG
American International Group
New York
|
+$12M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.53M |
| 4 |
TSC
Two Seas Capital
Rye,
New York
|
+$3.27M |
| 5 |
CC
Centiva Capital
New York
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$1.05M |
| 2 |
Renaissance Technologies
New York
|
-$335K |
| 3 |
VF
Virtu Financial
New York
|
-$203K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
-$201K |
| 5 |
SOW
State of Wyoming
Cheyenne,
Wyoming
|
-$35K |
ROIV Hedge Fund Activity: Q1 2022 in Review
52 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q1 2022, worth a combined $1.72B — down 50% from $3.42B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ROIV positions and 8 closed out — a net gain of 11 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Anchorage Capital Group, opening a new position worth an estimated $31.9M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $1.05M sold.
- 52 institutional investors held Roivant Sciences (ROIV) as of Q1 2022, up from 42 in Q4 2021.
- Funds reported $1.72B of Roivant Sciences stock for Q1 2022, down 50% quarter-over-quarter.
- 19 funds opened new Roivant Sciences positions in Q1 2022 and 8 closed out, a net change of +11 holders.
- The largest Roivant Sciences buyer in Q1 2022 was Anchorage Capital Group, an estimated $31.9M added.
- The largest Roivant Sciences seller in Q1 2022 was Pura Vida Investments, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2022.